HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NS 2028

structure in first source

Also Known As:

4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one; NS-2028; NS2028

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxadiazoles: 146
        NS 2028: 6
  - Oxazines: 9
    - NS 2028: 6

Experts

1.	Bai, Yang: 1 article (08/2021)
2.	Chang, Yu-Lin: 1 article (08/2021)
3.	Li, Yan: 1 article (08/2021)
4.	Wang, Jing-Zhou: 1 article (08/2021)
5.	Wang, Xu-Peng: 1 article (08/2021)
6.	Xin, Yue: 1 article (08/2021)
7.	Zhang, Li-Min: 1 article (08/2021)
8.	Zheng, Wei-Chao: 1 article (08/2021)
9.	Chuang, Victor T G: 1 article (09/2017)
10.	Ikeda, Mayumi: 1 article (09/2017)

Related Diseases

1.	Ischemia 01/01/2015 - "30 min of global ischemia increased LVDP to 121.9 ± 11.5% at 35 min of reperfusion of 2 μM NOC7 group and 2 μM NOC7 associated with NS2028 group from the ischemic control group (P < 0.05). " 01/01/2008 - "Eyecups of female Sprague-Dawley rats were incubated with PBS or the chemical ischemia mixture [iodoacetic acid (5 mM)/sodium cyanate (25 mM)] in the absence or presence of (1) arginine (0.05-2.0 mM), the substrate of nitric oxide synthase (NOS); (2) the NO donors sodium nitroprusside (SNP; 0.25-4.0 mM), 3-morpholinosydnonimine (SIN-1; 0.1, 0.3, 1.0 mM), SIN-1 (0.1 mM)/L-cysteine (5 mM, peroxynitrite scavenger), and NONOate (1, 5, 10 microM, slow NO releaser); (3) 8-Br-cGMP (0.1, 0.5, 1.0 mM); (4) BIM23014 (sst(2) receptor agonist; 1 microM), alone or in the presence of (5) the NOS inhibitor N(gamma)-monomethyl-L-arginine (NMMA; 0.5 mM); or (6) the guanylyl cyclase inhibitors 1H-[1,2,4]oxadiazolol [4,3-a]quinoxalin-1-one (ODQ;100 microM) and NS2028 (50 microM) for 60 minutes, at 5%CO(2)/air in 37 degrees C. "
2.	Prostatic Neoplasms (Prostate Cancer) 11/01/2008 - "The effects of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and 4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one (NS2028), both selective sGC inhibitors on proliferation, death and migration were determined in prostate cancer cell lines. "
3.	Inflammation (Inflammations) 02/01/2008 - "Moreover, the specific sGC inhibitor NS-2028 completely prevents ultraviolet B-irradiation-induced lymphatic vessel enlargement, edema formation, and skin inflammation in vivo. "
4.	Hemorrhage 08/01/2021 - "NS2028 (10 mg/kg), a blocker of sGC, was administrated at the onset of hemorrhage, but CORM-3 (4 mg/kg) was infused after resuscitation via femoral vein. "
5.	Edema (Dropsy) 02/01/2008 - "Moreover, the specific sGC inhibitor NS-2028 completely prevents ultraviolet B-irradiation-induced lymphatic vessel enlargement, edema formation, and skin inflammation in vivo. "

Related Drugs and Biologics

1.	NS 2028
2.	Peroxynitrous Acid (Peroxynitrite)
3.	Iodoacetic Acid
4.	Nitric Oxide Synthase (NO Synthase)
5.	Reactive Oxygen Species (Oxygen Radicals)
6.	Nitroprusside (Sodium Nitroprusside)
7.	Guanylate Cyclase (Guanylyl Cyclase)
8.	Cysteine (L-Cysteine)
9.	Arginine (L-Arginine)
10.	Soluble Guanylyl Cyclase

Related Therapies and Procedures

1.	Resuscitation